Abstract A077: Multi-pathway inhibition and synergistic anticancer activity of novel biguanides in triple negative breast cancer models
A novel treatment based on the biguanide metformin structure, termed JD006, which significantly inhibits TNBC cell growth in vitro and in vivo in a dose-dependent manner and at lower doses than its parental metformin, provides a strong preclinical rationale for combining next-generation biguanides with CDK4/6 inhibitor...